Initial P-glycoprotein expression in childhood acute lymphoblastic leukemia: No evidence of prognostic impact in follow-up

Pediatric Hematology and Oncology

Volumn 18, Issue 1, 2001, Pages 27-36

  Kanerva, Jukka ^a   Tiirikainen, Maarit I ^b   Mäkipernaa, Anne ^c   Riikonen, Pekka ^d   Möttönen, Merja ^e   Salmi, Toivo T ^f   Krusius, Tom ^g   Saarinen Pihkala, Ulla M ^h  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d KUOPIO UNIVERSITY HOSPITAL   (Finland)

^e OULU UNIVERSITY HOSPITAL   (Finland)

^f TURKU UNIVERSITY HOSPITAL   (Finland)

^g FINNISH RED CROSS BLOOD SERVICE   (Finland)

^h UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Childhood; Leukemia; Multiple drug resistance; P glycoprotein

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; GLYCOPROTEIN P; MERCAPTOPURINE; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN; PREDNISOLONE; PREDNISONE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; AGE; ARTICLE; BONE MARROW; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; FINLAND; FOLLOW UP; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; PROGNOSIS; PROTEIN EXPRESSION; RISK FACTOR; SEX; TREATMENT OUTCOME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFANT; KARYOTYPING; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MALE; P-GLYCOPROTEIN; PROGNOSIS;

EID: 0035155754     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.1080/088800101750059837     Document Type: Article

References (26)

1. Acute lymphoblastic leukemia
2. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia
3. Clinical significance of P-glycoprotein in multidrug resistance malignancies
4. Biochemistry of multidrug resistance mediated by the multidrug transporter
5. Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia
6. P-glycoprotein is an independent prognostic factor predicting relapse in childhood acute lymphoblastic leukaemia: Results of a 6-year prospective study
7. Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: Prognostic implications
8. P-glycoprotein and glutathione S-transferase pi in childhood acute lymphoblastic leukaemia
9. Clinical relevance of in vitro drug resistance testing in childhood acute lymphoblastic leukemia: The state of the art
10. Failure to detect the P-glycoprotein multidrug resistant phenotype in cases of resistant childhood acute lymphocytic leukaemia
11. Multiple drug resistance mediated by P-glycoprotein is not a major factor in a slow response to therapy in childhood ALL
12. Intensified treatment of acute childhood lymphoblastic leukaemia has improved prognosis, especially in non-high-risk patients: The Nordic experience of 2648 patients diagnosed between 1981 and 1996
13. Evaluation of red blood cell lysing solutions for the detection of intracellular antigens by flow cytometry
14. Multidrug resistance in pediatric malignancies
15. Expression of a multidrug-resistance gene in human tumors and tissues
16. Methods to detect P-Glycoprotein-associated multidrug resistance in patients' tumors: Consensus recommendations
17. Discordant P-glycoprotein antigen expression and transport function in acute myeloid leukemia
18. Correlation of P-glycoprotein expression and function in childhood acute leukemia: A children's cancer group study
19. Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glycoprotein associated with multi-drug-resistance
20. Binding diversity of antibodies against external and internal epitopes of the multidrug resistance gene product P-glycoprotein
21. Clinical significance of multidrug resistance p-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis
22. Low frequency of activity of P-glycoprotein (P-170) in acute lymphoblastic leukemia compared to acute myeloid leukemia
23. MDR1, MRP, topoisomerase Ilalpha/beta, and cyclin A gene expression in acute and chronic leukemias
24. Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia
25. Mdr1 gene expression in childhood acute lymphoblastic leukemias and lymphomas: A critical evaluation by four techniques
26. 2)